echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Research Articles > Twist Bioscience launches circulating tumor DNA reference standard, suitable for the development of liquid biopsy analysis

    Twist Bioscience launches circulating tumor DNA reference standard, suitable for the development of liquid biopsy analysis

    • Last Update: 2021-12-27
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    South San Francisco, California, USA--(Business Wire)--December 7, 2021--Twist Bioscience (NASDAQ: TWST) is a company that uses its silicon-based platform to provide high-quality synthetic DNA to help customers A successful company, the company announced the launch of the Twist cfDNA pan-cancer reference standard, a high-quality standardized control that can be used for the development and continuous monitoring of liquid biopsy tests to detect cancer through blood samples


    Liquid biopsy testing is a promising and evolving field in clinical oncology, which relies on NGS-based circulating tumor DNA (ctDNA) analysis


    Florian Battke, Head of Development Department of CeGaT GmbH, Germany, said: "With the increase in clinical validation experiments of liquid biopsy, a true ctDNA pan-cancer reference standard, rather than the few variants that are widely used today, will improve the ability of liquid biopsy to detect specific Accuracy in terms of oncogenes and mutations


    The Twist cfDNA pan-cancer reference standard material is composed of synthetically designed variant sequences and background DNA.


    Researchers can use this reference standard to assist the development of liquid biopsy analysis to establish the limit of detection (LoD) for specific cancer variants, and use it as a control to track the quality of the NGS analysis process to ensure the fidelity of the analysis process Degrees


    Twist cfDNA pan-cancer reference standards can be used in liquid biopsy procedures with Twist library preparation kit and Twist mechanical fragmentation kit to maximize efficacy, and provide a large number of different clinically relevant mutations, combined with first-class mutation synthesis methods, As well as excellent control over the frequency of specific target alleles, its form highly mimics the size distribution and fragmentation characteristics of cfDNA


    Dr.


    When developing and validating analyses, the use of appropriate reference materials is essential to assess the complexity and biological content of DNA in liquid biopsy samples


    When demonstrating the limit of detection (LoD) of ultra-sensitive liquid biopsy analysis based on NGS, the use of an accurate quantitative ctDNA control is the key


    About Twist Bioscience

    Twist Bioscience is a leading and fast-growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to promote the industrialization of bioengineering


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.